Alumis Inc.
ALMS
Kedudukan dalam Saham
#10025
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.63
Modal Pasaran
$858.16M
Perubahan (1 hari)
4.57%
Perubahan (1 tahun)
192.07%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
Pendapatan untuk Alumis Inc. (ALMS)
Pendapatan pada Mar 2025 TTM: $-268.52M
Menurut laporan kewangan terkini Alumis Inc., pendapatan semasa syarikat ialah $-268.52M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-381.64M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-64.77M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Alumis Inc. dari 2021 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-268.52M | 8.17% |
| 2024 | $-248.23M | -34.96% |
| 2023 | $-381.64M | 489.21% |
| 2022 | $-64.77M | 54.81% |
| 2021 | $-41.84M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -2,064.46% |
US
|
|
| $-3.09B | 1,049.65% |
US
|
|
| $-4.02B | 1,395.70% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -826.45% |
NL
|
